A First-in-Human Study of PRL3-ZUMAB

计划入组 38 人 · 首次发布于 2017 年 6 月 19 日

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors

计划入组 14 人 · 首次发布于 2019 年 10 月 8 日

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

计划入组 51 人 · 首次发布于 2020 年 7 月 1 日

PRL3-zumab

Protein C(Balfaxar, Beriplex, Ceprotin, Kcentra, Octaplex)

Protein-protein interaction inhibitors (Ajinomoto)

Protein Sciences Corporation

United States

HOUSE OF SUPPLEMENTS AUSTRALIA PTY LTD

Australia

Sanofi-Aventis Deutschland Gmbh

Sweden

Singapore-Developed Cancer Drug PRL3-zumab Shows Promise for Treating Vision Loss in AMD and Diabetic Retinopathy

Singapore's PRL3-zumab Shows Promise in Phase II Trial for Treatment-Resistant Solid Tumors

Elix and PRISM BioLab Partner to Revolutionize Drug Discovery for Protein-Protein Interaction Targets